ArticleAnnals of surgical treatment and research2014
Histopathologic factors affecting tumor recurrence after hepatic resection in colorectal liver metastases.
Article in Annals of surgical treatment and research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Diagnostic Accuracy of Sonazoid-Enhanced Ultrasonography for Detection of Liver Metastasis.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Histopathological prognostic factors for colorectal liver metastases: A systematic review and meta-analysis of observational studies.Histology and histopathology · 2021Pooled it
- Article
- Data-driven identification and semi-automated quantification of molecular targets for tumour-imaging of colorectal liver metastases and primary colorectal tumours.EJNMMI research · 2025Article
- The Determinants of Long-Term Outcomes After Colorectal Cancer Surgery: A Literature Review.Cureus · 2024Review
- Survival outcomes in unresectable metastatic rectal cancer patients after both primary site resection and chemoradiotherapy: a SEER-based observational study.Translational cancer research · 2022Article
- Contemporary evidence on colorectal liver metastases ablation: toward a paradigm shift in locoregional treatment.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2022Article
- Primary Tumor Resection for Rectal Cancer With Unresectable Liver Metastases: A Chance to Cut Is a Chance for Improved Survival.Frontiers in oncology · 2021Article
- Mutated DNA Damage Repair Pathways Are Prognostic and Chemosensitivity Markers for Resected Colorectal Cancer Liver Metastases.Frontiers in oncology · 2021Article
- Salvage RFA in patients with intrahepatic recurrence after major hepatic surgery for colorectal cancer liver metastases: mid-term outcome.European radiology · 2020Observational
- Prognostic significance of primary tumor sidedness in patients undergoing liver resection for metastatic colorectal cancer.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2019Observational
- Predictive factors of histological response of colorectal liver metastases after neoadjuvant chemotherapy.World journal of gastrointestinal oncology · 2019Article
- Preoperative neutrophil-lymphocyte ratio and CEA is associated with poor prognosis in patients with synchronous colorectal cancer liver metastasis.Annals of surgical treatment and research · 2019Article
- Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases.Cancer research and treatment · 2019Article
- Analysis of prognostic factors after resection of solitary liver metastasis in colorectal cancer: a 22-year bicentre study.Journal of cancer research and clinical oncology · 2018Observational
- NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway.Oncotarget · 2017Article
- Recurrence after hepatic resection in colorectal cancer liver metastasis -Review article-.Journal of medicine and life · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHepatic resection is a standard method of treatment for colorectal liver metastases (CRLM). However, the pathologic factors of metastatic lesions that affect tumor recurrence are less well defined in CRLM. The aim of this study was to evaluate the risk factors for recurrence of CRLM, focusing on histopathologic factors of metastatic lesions of the liver.
methodsFrom January 2003 to December 2008, 117 patients underwent curative hepatic resection for CRLM were reviewed. Tumor size and number, differentiation, tumor budding, angio-invasion, dedifferentiation and tumor infiltrating inflammation of metastatic lesions were investigated.
resultsThe mean number of hepatic tumors was 2 (range, 1-8). The mean size of the largest tumor was 2.9 cm (range, 0.3-18.5 cm) in diameter. The moderate differentiation of the hepatic tumor was the most common in 86.3% of the patients. Tumor budding, angio-invasion, and dedifferentiation were observed in 81%, 34%, and 12.8% of patients. Inflammation infiltrating tumor was detected in 6.8% of patients. Recurrence after hepatic resection appeared in 69 out of 117 cases (58.9%). Recurrence-free survival at 1, 2 and 5 years were 62.4%, 43.6%, and 34.3%. The multivariate analysis showed the number of metastases ≥3 (P = 0.007), the tumor infiltrating inflammation (P = 0.047), and presence of dedifferentiation (P = 0.020) to be independent risk factors for tumor recurrence.
conclusionHistopathological factors, i.e., dedifferentiation and tumor infiltrating inflammation of the metastatic lesion, could be one of the risk factors of aggressive behavior as well as the number of metastases even after curative resection for CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.